Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. (Q51889276)

17 April 2018

title

Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. (English)

1 reference

17 April 2018

0 references

1 reference

1 reference

1 reference

1 reference

1

1 reference

17 April 2018

Apiradee Theamboonlers

3

object named as

Apiradee Theamboonlers

1 reference

17 April 2018

Voranush Chongsrisawat

2

object named as

Voranush Chongsrisawat

1 reference

17 April 2018

author name string

Hans L Bock

4

1 reference

17 April 2018

Maarten Leyssen

5

1 reference

17 April 2018

Jeanne-Marie Jacquet

6

1 reference

17 April 2018

language of work or name

English

0 references

publication date

3 November 2009

1 reference

17 April 2018

published in

Vaccine

1 reference

17 April 2018

volume

28

1 reference

17 April 2018

issue

3

1 reference

17 April 2018

page(s)

730-736

1 reference

17 April 2018

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

The global impact of vaccination against hepatitis B: a historical overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

A review of the long-term protection after hepatitis A and B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Long-term protection of hepatitis B vaccine 18 years after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.074

10.1016/J.VACCINE.2009.10.074

7 January 2021

Identifiers

DOI

1 reference

17 April 2018

PubMed ID

19892043

1 reference

17 April 2018